Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) On track to initiate Phase 1 study in second quarter 2022 SAN DIEGO, May 12, 2022 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a…

Click here to view original post